SCNX Stock Catalyst: Scienture Holdings Adds Arbli Oral Suspension to Pediatric Formularies

Oct 2, 2026 · 7:48am ET

The addition covers three leading U.S. pediatric academic medical centers.

Max move

+42.9%

High of day $0.25

Sparker timei

7:48am ET

SCNX · Oct 2, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Scienture Holdings, Inc. announced on 2026-10-02 Scienture Holdings, Inc. announced that Arbli™ (losartan potassium) Oral Suspension, 10 mg/mL has been added to the formulary of three leading U.S. pediatric academic medical centers and hospitals.

The announcement cited $219 million, and 72 million prescriptions annually.

Scienture Holdings, Inc. has a free float of 30,912,847 shares and 41,064,146 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time SCNX sparks.

Download Sniper App →

Catch the next SCNX-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →